Stock IdeasStrong Buy Stocks

Strong Buy Stocks from Top Wall Street Analysts

Latest stocks with a Strong Buy rating from the top performing 25% of analysts tracked by WallStreetZen

Citigroup's Patrick B Donnelly raised their price target on Sotera Health Co (NASDAQ: SHC) by 9.5% from $21 to $23 on 2026/02/24. The analyst maintained their Strong Buy rating on the stock.

Sotera Health reported its Q4 and FY 2025 earnings.

Management provided FY 2026 guidance that calls for overall revenue growth of 5% to 6.5%, or $1.233B to $1.251B, and an adjusted EPS midpoint of $0.97, which is slightly higher than expected, Donnelly told readers.

"Management took a prudent approach in the guidance," the analyst opined.

Earnings Report

Sotera Health Co reported:

For Q4 2025:

• EPS of $0.26, which beat the Zacks Consensus Estimate of $0.24 and, by 23.8%, Q4 2024’s $0.21.
• Revenue of $303.44M, which beat the Zacks Consensus Estimate by 1.40% and, by 4.6%, Q4 2024’s $290.2M.

For FY 2025:

• EPS of $0.86, up 22.9% Y/Y.
• Revenue of $1.164B, up 5.7% Y/Y.

For FY 2026, management guided:

• EPS of $0.93 to $1.01.
• Revenue of $1.23B to $1.25B.

Chairman & CEO Michael B. Petras, Jr. commented: “The Company delivered strong results in 2025, driven by solid execution, increased demand for our mission‑critical services, and disciplined financial management.

“Sterigenics and Nordion delivered strong performance, each achieving high-single digit revenue growth for the year. 

“Nelson Labs delivered growth in core lab testing, while disciplined operational execution drove meaningful margin improvement. 

“This marks two decades of Y/Y revenue growth for the Company, which underscores the strength and resiliency of our business model.

“As we enter 2026, we are encouraged by our momentum and strengthened balance sheet, and we are confident in our ability to drive long‑term growth, strong free cash flow, and shareholder value as we remain on track to meet the financial goals presented at our 2024/11 investor day.”